[Effects of hydration on plasma concentrations of methotrexate in patients with osteosarcoma treated with high doses of methotrexate].
High dose of methotrexate (HDMTX) with leucovorin rescue requires over-hydratation to avoid nephrotoxicity; nevertheless the relationship between hydratation and plasma MTX levels is unknown. We compared the effects of two different types of hydratation (2 lt/m2 vs 1.5 lt/m2) on plasma MTX levels in two groups of patients with osteosarcoma of the extremities and treated with HDMTX (8 g/m2 IV). Samples were obtained at the end of infusion of MTX and 14 and 38 hours after the start of MTX infusion. At the end of infusion of MTX the medium plasma MTX levels proved significantly higher in the group with low hydratation than in the group with high hydratation (585.5 microns/l vs 427.7 microns/l P less than 0.001). The values obtained at 14 and 38 hours, did not show significant differences. No significant differences were seen between the two groups in term of late elimination of MTX and correlated toxicity. These data show that a low hydratation regime allows higher plasma MTX levels at the end of infusion of HDMTX and does not increase the incidence of late elimination of MTX compared to a high hydratation regime.
Ferrari
S
S
Centro Tumori dell'Apparato Locomotore, Istituto Ortopedico Rizzoli, Bologna.
Orlandi
M
M
Avella
M
M
Caldora
P
P
Ferraro
A
A
Ravazzolo
G
G
Bacci
G
G
D000328:Adult; D001859:Bone Neoplasms / Q000188:drug therapy*; D002648:Child; D005121:Extremities; D005260:Female; D005440:Fluid Therapy; D005950:Glucose Solution, Hypertonic; D006801:Humans; D007262:Infusions, Intravenous; D007668:Kidney / Q000187:drug effects; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage* / Q000009:adverse effects / Q000097:blood*; D012516:Osteosarcoma / Q000188:drug therapy*
D005950:Glucose Solution, Hypertonic; D002955:Leucovorin; D008727:Methotrexate
Effetto dell'idratazione sulle concentrazioni plasmatiche del methotrexate in pazienti con osteosarcoma trattati con alte dosi di methotrexate.